Prevtec Microbia Receives Market Authorization from USDA for Coliprotec® F4

MONTREAL, QUEBEC–(Marketwired – Jan 15, 2018) – Prevtec Microbia Inc. (“Prevtec”) is pleased to announce that it has received a market authorization from the Centre for Veterinary Biologics U.S. of the Department of Agriculture (USDA-CVB) to commercialize its vaccine Coliprotec® F4 in the US, a front line product against post […]

ANGLE plc: Notice of Results

GUILDFORD, SURREY–(Marketwired – Jan 10, 2018) – ANGLE plc (AIM: AGL) (OTCQX: ANPCY) For Immediate Release 10 January 2018 ANGLE plc (“ANGLE” or “the Company”) Notification of Interim Results and Webcast ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy company, will be releasing its interim results for the six months […]

TopiVert Pharma Limited: Positive results from TOP1288 Phase 1 study

LONDON, UNITED KINGDOM–(Marketwired – Jan 8, 2018) – TopiVert Pharma Ltd TopiVert announces positive results from the Phase 1 study with its oral formulation of TOP1288 for the treatment of ulcerative colitis London, UK, 8 January 2018: TopiVert Pharma Ltd (“TopiVert” or the “Company”), a clinical-stage biotechnology company developing Narrow […]

ANGLE plc: Prostate cancer ARV7 treatment biomarker

GUILDFORD, SURREY–(Marketwired – Jan 8, 2018) – (AIM: AG) (OTCQX: ANPCY) For immediate release   8 January 2018 ANGLE plc (“the Company”) RESEARCH DEMONSTRATES USE OF PARSORTIX™ LIQUID BIOPSY TO DETECT ARV7 IN PROSTATE CANCER AS A TREATMENT SELECTION BIOMARKER Parsortix-based ARV7 test may provide a wider understanding of ARV7 […]

Angle PLC: Holding(s) in Company

GUILDFORD, SURREY–(Marketwired – Dec 27, 2017) – Angle PLC (OTCQX: ANPCY) (AIM: AGL) AIM:AGL OTCQX:ANPCY TR-1: Standard form for notification of major holdings NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)i   1a. Identity of the issuer […]

Vernalis PLC: AGM Statement

WINNERSH, UNITED KINGDOM–(Marketwired – Dec 14, 2017) – Vernalis PLC (LSE: VER) 14 December 2017 LSE: VER AGM Statement Tuzistra® XR prescriptions continue to grow steadily, despite a reduction in narcotic prescribing Vernalis plc (“Vernalis” or the “Company”) provides an update ahead of its Annual General Meeting (“AGM”) being held […]

Vernalis + Daiichi Sankyo Enter Collaboration

WINNERSH, UNITED KINGDOM–(Marketwired – Dec 13, 2017) – Vernalis PLC (LSE: VER) 13 December 2017 LSE: VER Vernalis plc enters into research collaboration with Daiichi Sankyo Vernalis plc (LSE: VER) announced today that it has entered into a drug discovery collaboration with Daiichi Sankyo Company, Limited utilizing Vernalis’ fragment and […]

ANGLE plc Announces Parsortix Potential in Metastatic Breast Cancer

GUILDFORD, SURREY–(Marketwired – Dec 8, 2017) – ANGLE plc (AIM: AGL) (OTCQX: ANPCY) For immediate release  8 December 2017 AIM:AGL OTCQX:ANPCY ANGLE plc (“the Company”) GROUND-BREAKING WORK DEMONSTRATES POTENTIAL FOR PARSORTIX™ LIQUID BIOPSY TO REPLACE SOLID BIOPSY IN METASTATIC BREAST CANCER Direct comparison of a simple blood test processed with […]

Vernalis and Servier Achieve Research Milestone

WINNERSH, UNITED KINGDOM–(Marketwired – Dec 6, 2017) – Vernalis PLC (LSE: VER) 6 December 2017 LSE: VER Vernalis and Servier Achieve Research Milestone in Third Oncology Collaboration Vernalis plc and Servier today announce the achievement of a pre-clinical milestone in their third oncology drug discovery collaboration. Vernalis will receive a […]